Jane Wolstenholme
BA(Hons) (London), MSc (York), PhD (Nottingham)
Senior Health Economist, HERC
Jane Wolstenholme has 20 years of experience of conducting economic evaluations for health policy makers and exploring methodological issues relating to the design and analysis of economic evaluations. She has been a health economist at HERC since 1998.
Her main interests include designing and conducting economic evaluations alongside trials and cost-effectiveness models. She is principal investigator and co-applicant on a wide variety of funded research projects, across a number of disease areas and health-care technologies, including cancer, chronic kidney disease, obesity, mental health, point of care diagnostics. She is a health economics advisor for the RDS South Central and for the NIHR Diagnostics Evidence Co-Operative, Oxford. She supervises MSc and DPhil students. Jane has published widely and is co-author of a major OUP text book ‘Applied Methods of Cost-effectiveness Analysis in Health Care’.
Recent publications
-
Systematic review of health economic models for assessment and diagnosis of dementia
Journal article
Kwon J. et al, (2025), Alzheimer's & Dementia: Behavior & Socioeconomics of Aging, 1
-
NHS reference costs: a history and cautionary note.
Journal article
Amies-Cull B. et al, (2023), Health Econ Rev, 13
-
The early use of Antibiotics for At-risk children with InfluEnza in Primary Care (the ARCHIE programme)
Journal article
Wang K. et al, (2023), Programme Grants for Applied Research, 1 - 57
-
Estimating BMI distributions by age and sex for local authorities in England: a small area estimation study.
Journal article
Amies-Cull B. et al, (2022), BMJ Open, 12
-
Quality of life, healthcare use and costs in 'at-risk' children after early antibiotic treatment versus placebo for influenza-like illness: within-trial descriptive economic analyses of the ARCHIE randomised controlled trial.
Journal article
Rombach I. et al, (2022), BMJ Open, 12